Introduction: Benign prostatic hyperplasia is a prevalent chronic condition with expenditures exceeding $1 billion each year. Little is known about the treatment of patients by primary care physicians compared to urologists. We assessed changes in management after medication initiation in these 2 settings.
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Abbreviations and Acronyms
5-ARI = 5a-reductase inhibitor AB = alpha blocker BPH = benign prostatic hyperplasia LIS = low income subsidy PCP = primary care physician urologypracticejournal.com Benign prostatic hyperplasia is a frequent medical condition as men age. In 2000 approximately 4.5 million visits were made to physicians' offices for the primary diagnosis of BPH and almost 8 million visits were made with a primary or secondary diagnosis of BPH. 1 These visits and the treatment of men with symptomatic BPH are a significant burden to the health care system. In fact, BPH related spending exceeds $1 billion each year in the Medicare program alone. 2 Controlling costs of chronic conditions, like BPH, is a centerpiece of health care reform.
In the environment of cost control and health care reform, minimally morbid conditions such as BPH will be increasingly managed by the primary care physician. Medical therapies, alpha blockers and 5a-reductase inhibitors are efficacious as first line BPH therapies. 3e5 These medications have few side effects and are commonly prescribed by primary care physicians. However, complicated cases require additional care, including diagnostic testing and surgical interventions, that are not available through primary care physicians. Such patients may initiate care with urologists and may have different treatment trajectories than patients who begin care with PCPs. While differences in initial patient evaluation and treatment between PCP and urologist care have been assessed, and trends in BPH medication use investigated, attention has not focused on the subsequent treatment of patients in the 2 practice environments. 6, 7 In this study we assessed the changes in management after medication initiation among urologists and primary care physicians.
Materials and Methods

Cohort Development
From We also assessed the socioeconomic status of patients in the cohort. We determined which patients were dual eligible beneficiaries (qualifying for Medicare and Medicaid benefits). Dual eligible patients are more likely to be younger and poorer, to have a lower health status, to be institutionalized and to use more health care dollars than patients without this status. 9, 10 An additional determination of socioeconomic status was the patient's Medicare Part D coverage LIS. The LIS provides additional support for low income Medicare recipients for their drug coverage. We also determined patient use of primary care. Patients were grouped by the use of primary care from claims, with the categories of no primary care related claims, a single PCP related claim, multiple claims for a single PCP, majority of claims to a single PCP, majority of claims to 2 PCPs, majority of claims to nonprimary care with a single PCP, majority of claims to nonprimary care with 2 PCPs and, lastly, patients with 3 or more PCPs. Ambulatory care sensitive hospitalizations, a marker for primary care quality, were assessed through the use of the ICD-9 codes listed as the primary diagnosis from inpatient claims for 1 year before the index medication based on the methods of Weissman et al. 11 
Data Analysis
From this cohort we assessed the initial change in therapy for up to 4 years after medication initiation, namely adding a medication, switching medication, stopping medication or having surgery/retention. Medication initiation was the first filled prescription for the medication. We included new prescriptions for anticholinergic medications when determining addition of medication and changes in medication. The use of surgical therapy was determined from CPT codes for transurethral incision of the prostate, transurethral resection of the prostate, laser coagulation, laser vaporization, laser enucleation, transurethral microwave therapy, transurethral needle ablation, simple prostatectomy or other related BPH procedures.
Cases not sorted into these categories were considered stable on the initial medication. We used the Fine and Gray method to compare the cumulative incidence of competing risks. We estimated the cumulative incidence functions from competing risks data and tested equality across groups (PCP vs urologist) stratified by initial medical therapy (AB, 5-ARI or combination therapy) using the open source statistical program R. We used the package 'cmprsk' (competing risks) for this data analysis (Bob Gray 2014, cmprsk: Subdistribution Analysis of Competing Risks, R package version 2.2-7, http://CRAN.R-project.org/package¼cmprsk). In this package we used the function cuminc (cumulative incidence) to fit the cumulative incidence model and the function plot.cuminc (plot cumulative incidence) to plot the model in a graph. We then assessed the impact of starting medical therapy with a urologist vs PCP, controlling for patient age, urological conditions, race, socioeconomic status, comorbidity, region of patient residence and use of primary care with Cox proportional hazards regression.
Results
Demographic Analysis
In this cohort 8,573 men started BPH therapy with an alpha blocker or 5-ARI. Of these men 5,714 started medication with a PCP, 1,970 with a urologist, 335 had retention at initial therapy and 554 had an unknown type of prescribing physician. Patients starting care with urologists were more likely to be from the Northeast, to be white, to have a higher income and to have a lower comorbidity burden than patients who started care with a PCP (table 1) . Patients who started BPH medical care with urologists were more likely to receive fractured medical care without a usual medical care provider than patients who started care with a PCP. Not surprisingly, a significantly higher percentage of patients who started BPH medications with a urologist had other urological conditions present.
Changes in Medication Use
Men with initial treatment by a urologist were started on a 5-ARI or combination therapy more frequently than men started on therapy by a PCP (38% vs 22%, p <0.001). The most common change in treatment after medication initiation across almost all groups was stopping use of BPH related medication ( fig. 1 ). Urologists and PCPs had similar medication discontinuation and change rates when stratified by initial medication class (table 2). Use of surgery or development of retention was rare in the cohort, with minimal differences between urologists and PCPs. When controlling for multiple differences in baseline patient characteristics, patients who started care with primary care physicians were 
Analysis of Secondary Changes in Therapy
After an initial change in medical therapy for BPH most patients continued to have changes made to their BPH treatment regimen (66%) ( fig. 2 ). We examined secondary changes for patients (6,341) initially started on an AB. Of the 3,184 patients (50%) who stopped AB therapy, 1,797 (56%) stayed off medication. However, 1,044 patients (33%) restarted their medication. Among 142 patients who had surgery/retention, a minority (14 patients, 10%) continued with their AB. A significant minority (43 patients, 30%) had at least 1 subsequent retention episode, and finally 41 patients (29%) in this subset went off medication. Looking only at the subset of patients who underwent surgery after initial AB therapy (55 of the 142 with surgery/ retention), 24 stopped all medications after surgery (44% of surgically treated patients). We found no repeat surgery among the surgically treated patients. However, 9 patients (16%) did have a subsequent retention episode. We also looked at those who added a medication to their AB (467 patients). It was most common for these patients to stay on their AB and additional medication (237 patients, 51%). However, a significant minority had further medication changes (125 patients, 27%).
Discussion
Urologists were significantly more likely to prescribe 5-ARIs than PCPs as monotherapy or combination therapy.
Medication discontinuation was fairly common regardless of prescriber discipline. Surgery and urinary retention remained rare occurrences regardless of the initial care provider. Overall, patients were treated medically in similar ways in the primary care and urologist settings, except patients were more likely to remain on medical therapy if the therapy was initiated by a urologist.
In today's era of renewed focus on the costs of medical care, efficient care for chronic, prevalent conditions is emphasized. As a chronic, highly prevalent condition, BPH is a major driver of expense for elderly American men and the Medicare program. Specifically for BPH, treatment costs (1989 dollars) in the U.S. have been estimated to be as high as $6 billion ($4 billion for medical treatment and $2 billion for surgical procedures). 12 It is estimated that by 2030, 20%
of the United States population will be 65 years old or older and the fastest growing segment of the population would be those older than 85 years. 13 The growth of the elderly population portends significant financial pressures related to BPH care. With the development of safe and effective medical therapies, BPH has become a medically managed disease. Indeed, even in patients who start medical therapy with urologists, the cumulative incidence of surgery by 3 years after the initiation of therapy was less than 4%. As such, PCPs have a major role in the initial evaluation and treatment of BPH. In a review of data from MCARE, a regional Figure 2 . Analysis of secondary and tertiary medication changes for those initiated on alpha blocker. Half of patients who began AB therapy discontinued medication (go off medication 3,184 patients). In this group approximately a third restarted AB during followup (restart AB 1,044 patients). Surgery or retention was rare event as secondary (142 patients, 2%) or tertiary change (195 patients, 5% of all tertiary changes) after initial medical therapy.
health maintenance organization, a significant majority of patients with BPH were initially treated by PCPs. 6 With the low rates of surgery and retention in our study, this shift to PCP management appears warranted. Furthermore, although PCPs use advanced testing for patients with BPH far less commonly than urologists, 6,14 our study shows that medication changes were similar in patients cared for by PCPs vs urologists.
Initial medical care for BPH by the PCP is important since the urology workforce cannot keep up with the projected demand for its services. The number of urologists in the United States peaked in 2009 and is now decreasing, especially in rural areas. When taking the increasing population size into account, the supply of urologists per capita has been in decline since 1981. 15 Pruthi et al forecast a 29%
reduction in the total number of urologists by 2025. 15 Given this decline, and a freeze in the number of urology trainee positions since 1997, there may be an inevitable shift in the initial care and treatment of prevalent conditions like BPH to the primary care physician. The patient centered medical home is a health care reform meant to eliminate fragmented medical care and, in turn, eliminate wasteful inefficiencies in the medical sector. For most conditions PCPs are likely best to lead the group as a patient's personal physician. While some have argued that for genitourinary cancers, urologists may be best suited to provide a medical home, 16 the disproportionately small number of urologists compared to the burden of BPH precludes urologists from serving as the medical home for such a prevalent condition. Instead, urologists could be used as a referral for those with abnormal lower urinary tract symptoms not clearly due to BPH, severe symptoms not likely or able to be managed with medical therapy alone, or patients with urinary retention.
Urologists have a vital role in BPH care, especially for these more complex cases. We found patients with other urological conditions were more commonly treated by urologists than by PCPs. These patients have more diagnoses, other conditions requiring evaluation and management, and the need for the advanced testing available only through a urologist's specialized skills and training. Beyond these advanced cases, urologists provide potentially better care since they are more likely, in our study and others, than PCPs to prescribe 5-ARIs. 6 Furthermore, patients treated by urologists were more likely to continue medical therapy for BPH than patients with care initiation by PCPs. The increased use of 5-ARIs by urologists, and greater compliance with medical therapy among patients treated initially by urologists may, from prior randomized trials, translate into decreased downstream complications for patients related to their BPH. 4 Despite treating potentially more complex cases, turning to surgery was still rare among urologists, suggesting that urologists are using clinical discretion in surgical care. Our study has some limitations. Our patient population was drawn from a 5% sample of Medicare beneficiaries ranging in age from 66 to 90 years. While symptomatic BPH does develop in younger men, the cohort we examined covers the ages with the greatest prevalence of BPH. We also examined medication use from the perspective of filled prescriptions. We cannot be certain that patients actually used the prescriptions they were given. However, the discontinuation rates seen in our study would only be increased if the filled prescriptions were not being used. We were also unable to gauge patient symptom severity. In addition, we were not able to assess why a change in BPH management occurred. Possible reasons for medication discontinuation include medication failure, intolerable side effects and cessation of symptoms, and greater compliance by patients treated by urologists could be related to a higher symptom burden at baseline.
Conclusions
Patients with initial medical management of BPH by urologists discontinued all medical therapy less frequently than those who initiated medical management with PCPs. However, in both groups surgery and retention were rare events. With the lack of growth of the urology workforce and the increasing size of the American elderly population, these findings suggest that primary care is the best setting for most men to initiate BPH care, with urologists serving as expert resources for complex or advanced cases that do not respond to initial medical therapy.
